FHC
RARE icon

First Horizon Corporation’s Ultragenyx Pharmaceutical RARE Stock Holding History

First Horizon Corporation’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-169
Closed -$3.89K – 1531
2025
Q4 		$3.89K Buy
169
+5
+3% +$164 ﹤0.01% 1245
2025
Q3 		$4.93K Buy
+164
New +$4.92K ﹤0.01% 1185

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Horizon Corporation's RARE Position: Q1 2026 in Review

First Horizon Corporation sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 169 shares — an estimated $3.89K sold.

First Horizon Corporation first reported a position in RARE in Q3 2025 and held it in 2 quarters. The position peaked at $4.93K in Q3 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • First Horizon Corporation reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • First Horizon Corporation sold 169 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.89K.
  • First Horizon Corporation first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 2 quarters.
  • First Horizon Corporation's Ultragenyx Pharmaceutical position peaked at $4.93K in Q3 2025.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on First Horizon Corporation's 13F filing for Q1 2026, filed 30 Apr 2026.